Literature DB >> 15170667

Pathways of urothelial cancer progression suggested by Bayesian network analysis of allelotyping data.

Svetlana Bulashevska1, Orsolya Szakacs, Benedikt Brors, Roland Eils, Gyula Kovacs.   

Abstract

Urothelial cancers of the bladder (UC) comprise biologically heterogeneous group of tumors and display complex genetic alterations. Several genetic changes have been analyzed in detail and some of them are associated with the development and progression of UCs. Only a few studies, however, are focused on identifying the order in which the aberrations may appear during UC tumorigenesis. We have analyzed 123 papillary UCs of the bladder by microsatellites for each of the chromosomal regions that have been suggested to be specifically involved in this type of tumor. We used Bayesian network modeling that enables to uncover multivariate probabilistic dependencies between variables. This methodology applied to LOH data allowed us to discover patterns of losses in UCs. Exploiting the mechanism of probabilistic reasoning in Bayesian networks we suggest primary and secondary events in tumor pathogenesis and reconstruct the possible flow of progression of allelic changes. Losses of chromosome 9p and 9q were found to be the primary events. Losses of 8p and 17p are important events leading to progression of tumor cell clones. The loss of 17p occurs when both abnormalities of chromosome 9 and 8p are already present. There are chromosomal losses related to 8p (1q, 18q, 10q) and some losses like 5q/5p were associated with 17p, leading to the hypothesis of different genetic pathways of UC progression. The abnormalities of chromosome regions 13q, 16q, 6q, 14q, 3p are suggested to be late events being accumulated during the progression of cancer. Although some genetic changes were associated only with the 8p pathway, most secondary genetic changes appear in both pathways. Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat/index.html. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15170667     DOI: 10.1002/ijc.20180

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  6 in total

1.  Analysis of the copy number profiles of several tumor samples from the same patient reveals the successive steps in tumorigenesis.

Authors:  Eric Letouzé; Yves Allory; Marc A Bollet; François Radvanyi; Frédéric Guyon
Journal:  Genome Biol       Date:  2010-07-22       Impact factor: 13.583

Review 2.  Molecular pathogenesis of bladder cancer.

Authors:  Margaret A Knowles
Journal:  Int J Clin Oncol       Date:  2008-08-15       Impact factor: 3.402

3.  NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.

Authors:  Patricia C Galipeau; Xiaohong Li; Patricia L Blount; Carlo C Maley; Carissa A Sanchez; Robert D Odze; Kamran Ayub; Peter S Rabinovitch; Thomas L Vaughan; Brian J Reid
Journal:  PLoS Med       Date:  2007-02       Impact factor: 11.069

4.  Identifying restrictions in the order of accumulation of mutations during tumor progression: effects of passengers, evolutionary models, and sampling.

Authors:  Ramon Diaz-Uriarte
Journal:  BMC Bioinformatics       Date:  2015-02-12       Impact factor: 3.169

5.  Detection of specific chromosomal aberrations in urine using BCA-1 (oligo-CGH-array) enhances diagnostic sensitivity and predicts the aggressiveness of non-muscle-invasive bladder transitional cell carcinoma.

Authors:  Olivier Cussenot; Karim Sighar; Mansoor Mohammed; Sylvain Hugonin; Valérie Ondet; Stéphane Larre; Roger Lacave; Morgan Roupret; Géraldine Cancel-Tassin
Journal:  World J Urol       Date:  2013-11-07       Impact factor: 4.226

6.  Mutation Enrichment and Transcriptomic Activation Signatures of 419 Molecular Pathways in Cancer.

Authors:  Marianna A Zolotovskaia; Victor S Tkachev; Alexander P Seryakov; Denis V Kuzmin; Dmitry E Kamashev; Maxim I Sorokin; Sergey A Roumiantsev; Anton A Buzdin
Journal:  Cancers (Basel)       Date:  2020-01-22       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.